Study of Perampanel for ALS Stopped Due to Adverse Events

Study of Perampanel for ALS Stopped Due to Adverse Events

311500

Study of Perampanel for ALS Stopped Due to Adverse Events

A small open-label study evaluating the epilepsy medication perampanel in adults with amyotrophic lateral sclerosis (ALS) was halted due to adverse events that affected behavior. Despite the findings, larger clinical trials investigating perampanel in ALS patients are ongoing, which might determine if the medication contributed to behavioral side effects. The study, “An open label pilot study of the safety and tolerability of perampanel in amyotrophic lateral sclerosis,” was published in the journal Muscle & Nerve. Perampanel,…

You must be logged in to read/download the full post.